ACE insertion/deletion (I/D) polymorphism and diabetic nephropathy

Journal of Nephropathology

Volumn 1, Issue 3, 2012, Pages 143-151

  Rahimi, Zohreh ^a  

^a KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

ACE activity; ACE I D polymorphism; ACE inhibitors; Angiotensin II receptor blockers; Diabetic nephropathy

Indexed keywords

EID: 84874748042     PISSN: 22518363     EISSN: 22518819     Source Type: Journal    
DOI: 10.5812/nephropathol.8109     Document Type: Review

References (55)

1. Rahimi Z, Hasanvand A, Fellehgary V. Interaction of MTHFR 1298C with ACE D allele augments the risk of diabetic nephropathy in Western Iran. DNA Cell Biol. 2012;31(4):553-9.
2. Jafari Y, Rahimi Z, Vaisi-Raygani A, Rezaei M. Interaction of eNOS polymorphism with MTHFR variants increase the risk of diabetic nephropathy and its progression in type 2 diabetes mellitus patients. Mol Cell Biochem. 2011;353(1-2):23-34.
3. Shin Shin Y, Baek SH, Chang KY, Park CW, Yang CW, Jin DC, et al. Relations between eNOS Glu298Asp polymorphism and progression of diabetic nephropathy. Diabetes Res Clin Pract. 2004; 65: 257–65;65(3):257-65.
4. Rigat B, Hubert C, Alhenc-Gelas F, Cambien F, Corvol P, Soubrier F. An insertion/deletion polymorphism in the angiotensin I-converting enzyme gene accounting for half the variance of serum enzyme levels. J Clin Invest. 1990;86(4):1343-6.
5. Felehgari V, Rahimi Z, Mozafari H, Vaisi-Raygani A. ACE gene polymorphism and serum ACE activity in Iranians type II diabetic patients with macroalbuminuria. Mol Cell Biochem. 2011;346(1-2):23-30.
6. Arfa I, Abid A, Nouira S, Elloumi-Zghal H, Malouche D, Mannai I, et al. Lack of association between the angiotensin- converting enzyme gene (I/D) polymorphism and diabetic nephropathy in Tunisian type 2 diabetic patients. J Renin Angiotensin Aldosterone Syst. 2008; 9:32–6;9(1):32-6.
7. Shanmugam V, Sell KW, Saha BK. Mistyping ACE heterozygotes. PCR Methods Appl. 1993;3(2):120-1.
8. Eleni S, Dimitrios K, Vaya P, Areti M, Norma V, Magdalini G. Angiotensin-I converting enzyme gene and I/D polymorphism distribution in the Greek population and a comparison with other European populations. J Genet. 2008;87(1):91-3.
9. Zhou JB, Yang JK, Lu JK, An YH. Angiotensin-converting enzyme gene polymorphism is associated with type 2 diabetes: a meta-analysis. Mol Biol Rep. 2010;37(1):67-73.
10. Rahimi Z, Felehgari V, Rahimi M, Mozafari H, Yari K, Vaisi-Raygani A, et al. The frequency of factor V Leiden mutation, ACE gene polymorphism, serum ACE activity and response to ACE inhibitor and angiotensin II receptor antagonist drugs in Iranians type II diabetic patients with microalbuminuria. Mol Biol Rep. 2011;38(3):2117-23.
11. Nikzamir A, Nakhjavani M, Esteghamati A, Rashidi A. Correlates of ACE activity in macroalbuminuric type 2 diabetic patients treated with chronic ACE inhibition. Nephrol Dial Transplant. 2008;23(4):1274-7.
12. Ruggenenti P, Bettinaglio P, Pinares F, Remuzzi G. Angiotensin converting enzyme insertion/deletion polymorphism and renoprotection in diabetic and nondiabetic nephropathies. Clin J Am Soc Nephrol. 2008;3(5):1511-25.
13. Raptis A.E, Viberti G. Pathogenesis of diabetic nephropathy Exp Clin Endocrinol Diabetes. 2001;2(109):424-37.
14. Chawla T, Sharma D, Singh A. Role of the renin angiotensin system in diabetic nephropathy. World J diabetes. 2010;1(5):141-5. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3083897/.
15. Rahimi Z, Rahimi Z, Mozafari H, Parsian A. Preeclampsia and angiotensin converting enzyme (ACE) I/D and angiotensin II type-1 receptor (AT1R) A1166C polymorphisms: association with ACE I/D polymorphism. J Renin Angiotensin Aldosterone Syst. 2012;.
16. Hadjadj S, Fumeron F, Roussel R, Saulnier PJ, Gallois Y, Ankotche A, et al. Prognostic value of the insertion/ deletion polymorphism of the ACE gene in type 2 diabetic subjects. Diabetes Care. 2008;31(9):1847-52.
17. Movva S, Alluri RV, Komandur S, Vattam K, Eppa K, Mukkavali KK, et al. Relationship of angiotensin-converting enzyme gene polymorphism with nephropathy associated with type 2 diabetes mellitus in Asian Indians. J Diabetes Complications. 2007;21(4):237-241.
18. Ng DP, Tai BC, Koh D, Tan KW, Chia KS. Angiotensin- I converting enzyme insertion/deletion polymorphism and its association with diabetic nephropathy: a meta-analysis of studies reported between 1994 and 2004 and comprising 14,727 subjects. Diabetologia. 2005;48(5):1008-16.
19. Hadjadj S, Tarnow L, Forsblom C, Kazeem G, Marre M, Groop PH, et al. Association between angiotensinconverting enzyme gene polymorphisms and diabetic nephropathy: case-control, haplotype, and family-based study in three European populations. J Am Soc Nephrol. 2007;18(4):1284-91.
20. Nikzamir A, Esteghamati A, Feghhi M, Nakhjavani M, Rashidi A, Reza JZ. The insertion/ deletion polymorphism of the angiotensinconverting enzyme gene is associated with progression, but not development, of albuminuria in Iranian patients with type 2 diabetes. J Renin-Angiotensin- Aldosterone Syst. 2009;10(2):109-4.
21. Ahluwalia TS, Ahuja M, Rai TS, Kohli HS, Bhansali A, Sud K, et al. ACE variants interact with the RAS pathway to confer risk and protection against type 2 diabetic nephropathy. DNA Cell Biol. 2009; 28: 141-50;28(3):141-50.
22. Ezzidi I, Mtiraoui N, Kacem M, Chaieb M, Mahjoub T, Almawi WY. Identification of specific angiotensin-converting enzyme variants and haplotypes that confer risk and protection against type 2 diabetic nephropathy. Diabetes Metab Res Rev. 2009;25(8):717-24.
23. Staessen JA, Wang JG, Ginocchio G, Petrov V, Saavedra AP, Soubrier F, et al. The deletion/insertion polymorphism of the angiotensin converting enzyme gene and cardiovascular- renal risk. J Hypertens. 1997;15(12 Pt 2):1579-92.
24. Ng D, Ramli SNB, Chia KS, Koh D, Tai BC. Genetic variation at the angiotensin-I converting enzyme locus and the risk for diabetic nephropathy: A study based on 53 studies and 17 791 subjects. Salud I Ciencia. 2009;16:751-754.
25. Wang F, Fang Q, Yu N, Zhao D, Zhang Y, Wang J, et al. Association between genetic polymorphism of the angiotensin converting enzyme and diabetic nephropathy: a meta-analysis comprising 26580 subjects. J Renin Angiotensin Aldosterone Syst. 2012;13(1):161-74.
26. Wang Y, Ng MC, So WY, Tong PC, Ma RC, Chow CC, et al. Prognostic effect of insertion/deletion polymorphism of the ace gene on renal and cardiovascular clinical outcomes in Chinese patients with type 2 diabetes. Diabetes Care. 2005;28(2):348-54.
27. Marre M, Bouhanick B, Berrut G, Gallois Y, Le Jeune JJ, Chatellier G, et al. Renal changes on hyperglycemia and angiotensin-converting enzyme in type 1 diabetes. Hypertension. 1999;33(3):775-80.
28. Eroglu Z, Cetinkalp S, Erdogan M. Association of the angiotensinogen M235T and angiotensin-converting enzyme insertion/deletion gene polymorphism in Turkish type 2 diabetic patients with and without nephropathy. J Diabetes Complications. 2008;22(3):186-90.
29. Palomo-Pinon S, Gutierrez-Rodriguez ME, Diaz-Flores M, Sanchez-Barrera R, Valladares-Salgado A, Utrera-Barillas D, et al. DD genotype of angiotensin converting enzyme in type 2 diabetes mellitus with renal disease in Mexican mestizos. Nephrology (Carlton). 2009;14(2):235-9.
30. Rahimi Z, Vaisi-Raygani A, Rahimi Z, Parsian A. The concomitant presence of eNOS 894T and ACE D alleles are associated with diabetic nephropathy in Kurdish population from Western Iran. Nephrology (Carlton). 2012;17(2):175-81.
31. Rahimi M, Hasanvand A, Rahimi Z, Vaisi-Raygani A, Mozafari H, Rezaei M, et al. Synergistic Effects of the MTHFR C677T and A1298C polymorphisms on the increase risk of micro- and macro-albuminuria and progression of diabetic nephropathy among Iranians with type 2 diabetes mellitus. Clin Biochem. 2010;43(16-17):1333-9.
32. Yu ZY, Chen LS, Zhang LC, Zhou TB. Meta-analysis of the relationship between ACE I/D gene polymorphism and end-stage renal disease in patients with diabetic nephropathy. Nephrology (Carlton). 2012;17(5):480-7.
33. Manea SA, Robciuc A, Guja C, Heltianu C. Identification of gene variants in NOS3, ET-1 and RAS that confer risk and protection against microangiopathy in type 2 diabetic obese subjects. Biochem Biophys Res Commun. 2011 15;407(3):486-90.
34. Kalaitzidis R, Bakris GL. Effects of angiotensin II receptor blockers on diabetic nephropathy. J Hypertension. 2009;27:S15-S21.
35. Nakayama Y, Nonoguchi H, Kohda Y, Inoue H, Memetimin H, Izumi Y, et al. Different mechanisms for the progression of CKD with ACE gene polymorphisms. Nephron Clin Pract. 2009;111(4):C240-C46.
36. Vegter S, Perna A, Hiddema W, Ruggenenti P, Remuzzi G, Navis G, et al. Cost effectiveness of ACE inhibitor therapy to prevent dialysis in nondiabetic nephropathy: Influence of the ACE insertion/deletion polymorphism. Pharmacogenet Genomics. 2009;19(9):695-703.
37. So WY, Ma RC, Ozaki R, Tong PC, Ng MC, Ho CS, et al. Angiotensin converting enzyme (ACE) inhibition in type 2, diabetic patients: interaction with ACE insertion/ deletion polymorphism. Kidney Int. 2006;69(8):1438-43.
38. Ha SK, Yong Lee S, Su Park H, Ho Shin J, Jung Kim S, Hun Kim D, et al. ACE DD genotype is more susceptible than ACE II and ID genotypes to the antiproteinuric effect of ACE inhibitors in patients with proteinuric non-insulin- dependent diabetes mellitus. Nephrol Dial Transplant. 2000;15:1617-23.
39. Penno G, Chaturvedi N, Talmud PJ, Cotroneo P, Manto A, Nannipieri M, et al. Effect of angiotensin converting enzyme (ACE) gene polymorphism on progression of renal disease and the influence of ACE inhibition in IDDM patients: findings from the EUCLID randomized controlled trial. EURODIAB controlled trial of lisinopril in IDDM. Diabetes. 1998;47:1507-11.
40. Weekers L, Bouhanick B, Hadjadj S, Gallois Y, Roussel R, Pean F, et al. Modulation of the renal response to ACE inhibition by ACE insertion/deletion polymorphism during hyperglycemia in normotensive, normoalbuminuric type 1 diabetic patients. Diabetes. 2005;54:2961-7.
41. Parving HH, de Zeeuw D, Cooper ME, Remuzzi G, Liu N, Lunceford J, et al. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. J Am Soc Nephrol. 2008;19:771-9.
42. Andersen S, Tarnow L, Cambien F, Rossing P, Juhl TR, Deinum J, et al. Renoprotective effects of losartan in diabetic nephropathy: interaction with ACE insertion/ deletion genotype? Kidney Int. 2002;62:192-198.
43. Jacobsen PK. Preventing end stage renal disease in diabetic patients: genetic aspect (part I). J Renin Angiotensin Aldosterone Syst. 2005;6:1-14.
44. Parving HH, Jacobsen P, Tarnow L, Rossing P, Lecerf L, Poirier O, et al. Effect of deletion polymorphism of angiotensin converting enzyme gene on progression of diabetic nephropathy during inhibition of angiotensin converting enzyme: observational follow up study. BMJ. 1996;313:591-4.
45. Aggarwal S, Dimri N, Tandon I, Agarwal S. Preeclampsia in North Indian women: the contribution of genetic polymorphisms. J Obstet Gynaecol Res. 2011;37(10):1335-41.
46. Dickson ME, Zimmerman MB, Rahmouni K, Sigmund CD. The -20 and -217 Promoter variants dominate differential angiotensinogen haplotype regulation in angiotensinogen- expressing cells. Hypertension. 2007;49(3):631-9.
47. Lovati E, Richard A, Frey BM, Frey FJ, Ferrari P. Genetic polymorphisms of the renin-angiotensin-aldosterone system in end-stage renal disease. Kidney Int. 2001;60(1):46-54.
48. Jacobsen P, Tarnow L, Carstensen B, Hovind P, Poirier O, Parving HH. Genetic variation in the renin-angiotensin system and progression of diabetic nephropathy. J Am Soc Nephrol. 2003;14(11):2843-50.
49. Bantis C, Ivens K, Kreusser W, Koch M, Klein-Vehne N, Grabensee B, et al. Influence of genetic polymorphisms of the renin-angiotensin system on IgA nephropathy. Am J Nephrol. 2004;24:258-67.
50. Osawa N, Koya D, Araki S, Uzu T, Tsunoda T, Kashiwagi A, et al. Combinational effect of genes for the reninangiotensin system in conferring susceptibility to diabetic nephropathy. J Hum Genet. 2007;52:143-151.
51. Miyamoto Y, Saito Y, Kajiyama N, Yoshimura M, Shimasaki Y, Nakayama M, et al. Endothelial nitric oxide synthase gene is positively associated with essential hypertension. Hypertension. 1998;32(1):3-8.
52. Stratta P, Bermond F, Guarrera S, Canavese C, Carturan S, Dall’Omo A, et al. Interaction between gene polymorphisms of nitric oxide synthase and renin-angiotensin system in the progression of membranous glomerulonephritis. Nephrol Dial Transplant. 2004;19:587-95.
53. Moczulski D, Fojcik H, Zukowska-Szczechowska E, Szydlowska I, Grzeszczak W. Effects of the C677T and A1298C polymorphisms of the MTHFR gene on the genetic predisposition for diabetic nephropathy. Nephrol Dial Transplant. 2003;18:1535-40.
54. Sun J, Xu Y, Zhu Y, Lu H. Genetic polymorphism of methylenetetrahydrofolate reductase as a risk factor for diabetic nephropathy in Chinese type 2 diabetic patients. Diabetes Res Clin Pract. 2004;64(3):185-90.
55. Mtiraoui N, Ezzidi I, Chaieb M, Marmouche H, Aouni Z, Chaieb A, et al. MTHFR C677T and A1298C gene polymorphisms and hyperhomocysteinemia as risk factors of diabetic nephropathy in type 2 diabetes patients. Diabetes Res Clin Pract. 2007;75(1):99-106.